Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T3011 Monotherapy and Combination in Advanced Solid Tumors
NCT04780217Phase 2Active, not recruiting
- Sponsor
- ImmVira
- Start
- Aug 2021
- Primary completion
- Mar 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label trial of MVR-T3011 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC) and 3 more (2 arms), sponsored by ImmVira. Primary endpoints: Safety and Tolerability of escalating doses at 2 years, Dose Limiting Toxicities at 2 years and 2 more. Started Aug 2021; status: active, not recruiting.
02
Drugs
MVR-T3011
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)colorectal cancer (CRC)ovarian cancer
Beyond the preview
Go deeper on NCT04780217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04780217.